Xemperia

XEMPERIA, founded in 2023 as a spin-off from the University of Fribourg, Switzerland, leverages over 25 years of pioneering expertise in translational cancer research and biomarker discovery.

Our vision is to lead the development of innovative blood tests for cancer detection and monitoring, empowering doctors to make informed therapeutic decisions.

Our mission is to reduce cancer mortality and improve patients' quality of life by enabling the earliest possible detection and treatment of cancer.

At XEMPERIA, we harness the body's natural responses to cancer, identifying cancer-associated biomarkers in the blood through cutting-edge multiomics methodologies.

Our flagship project focuses on a blood test for the early detection of breast cancer, utilizing the immune system's response to the disease. This test has successfully completed an initial phase of clinical validation, and we are now preparing for a large-scale validation study, aiming for certification and commercialization by 2028.

Simultaneously, XEMPERIA is advancing DNA-based nanosensors for detecting RNA/DNA, offering rapid, sensitive, and cost-effective cancer detection. Initially developed for research purposes, these tests have the potential for future clinical applications.